Allan D Sniderman

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4090705/publications.pdf

Version: 2024-02-01

155 papers	9,766 citations	41344 49 h-index	38395 95 g-index
162 all docs	162 docs citations	162 times ranked	9373 citing authors

#	Article	IF	Citations
1	Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the) Tj ETQq1 1 0.784314 rgBT /Ove	13.7	693
2	2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult â€“ 2009 recommendations. Canadian Journal of Cardiology, 2009, 25, 567-579.	1.7	653
3	Application of New Cholesterol Guidelines to a Population-Based Sample. New England Journal of Medicine, 2014, 370, 1422-1431.	27.0	571
4	A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 337-345.	2.2	491
5	Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiology, 2019, 4, 1287.	6.1	299
6	Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease. Circulation, 2015, 131, 451-458.	1.6	283
7	Hypertriglyceridemic HyperapoB: The Unappreciated Atherogenic Dyslipoproteinemia in Type 2 Diabetes Mellitus. Annals of Internal Medicine, 2001, 135, 447.	3.9	273
8	Association of Hyperapobetalipoproteinemia with Endogenous Hypertriglyceridemia and Atherosclerosis. Annals of Internal Medicine, 1982, 97, 833.	3.9	267
9	Why might South Asians be so susceptible to central obesity and its atherogenic consequences? The adipose tissue overflow hypothesis. International Journal of Epidemiology, 2007, 36, 220-225.	1.9	263
10	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. Journal of Clinical Lipidology, 2011, 5, 338-367.	1.5	235
11	The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk. Clinical Chemistry and Laboratory Medicine, 2004, 42, 1355-63.	2.3	216
12	Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. American Journal of Cardiology, 2003, 91, 1173-1177.	1.6	196
13	Why Guideline-Making Requires Reform. JAMA - Journal of the American Medical Association, 2009, 301, 429.	7.4	184
14	Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. American Journal of Cardiology, 2004, 93, 159-164.	1.6	157
15	The Severe Hypercholesterolemia Phenotype. Journal of the American College of Cardiology, 2014, 63, 1935-1947.	2.8	153
16	Comparison of the Associations of Apolipoprotein B and Non-High-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in Patients With the Metabolic Syndrome in the Insulin Resistance Atherosclerosis Study. Circulation, 2004, 110, 2687-2693.	1.6	135
17	Effect of acylation stimulating protein on the triacylglycerol synthetic pathway of human adipose tissue. Lipids, 1991, 26, 495-499.	1.7	132
18	Age as a modifiable risk factor for cardiovascular disease. Lancet, The, 2008, 371, 1547-1549.	13.7	125

#	Article	IF	Citations
19	Comparison of the Associations of Apolipoprotein B and Low-Density Lipoprotein Cholesterol With Other Cardiovascular Risk Factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation, 2003, 108, 2312-2316.	1.6	122
20	Discordance Between Apolipoprotein B and LDL-Cholesterol in Young Adults Predicts Coronary Artery Calcification. Journal of the American College of Cardiology, 2016, 67, 193-201.	2.8	120
21	Quantifying Importance of Major Risk Factors for Coronary Heart Disease. Circulation, 2019, 139, 1603-1611.	1.6	115
22	Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C. European Journal of Preventive Cardiology, 2015, 22, 1321-1327.	1.8	112
23	Discordance analysis of Apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis, 2012, 225, 444-449.	0.8	105
24	Relations of Change in Plasma Levels of LDLâ€C, Nonâ€HDLâ€C and apoB With Risk Reduction From Statin Therapy: A Metaâ€Analysis of Randomized Trials. Journal of the American Heart Association, 2014, 3, e000759.	3.7	104
25	Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement. Journal of Clinical Lipidology, 2011, 5, 264-272.	1.5	103
26	Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice. Journal of Clinical Lipidology, 2008, 2, 36-42.	1.5	101
27	Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nature Reviews Endocrinology, 2010, 6, 335-346.	9.6	99
28	Proportion of US Adults Potentially Affected by the 2014 Hypertension Guideline. JAMA - Journal of the American Medical Association, 2014, 311, 1424.	7.4	95
29	The adipocyte life cycle hypothesis. Clinical Science, 2006, 110, 1-9.	4.3	85
30	Why is nonâ^'high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?. Journal of Clinical Lipidology, 2010, 4, 152-155.	1.5	83
31	The Necessity for Clinical Reasoning in the Era of Evidence-Based Medicine. Mayo Clinic Proceedings, 2013, 88, 1108-1114.	3.0	77
32	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clinical Chemistry, 2017, 63, 870-879.	3.2	74
33	A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 608-618.	2.8	68
34	Hyperapobetalipoproteinemia: the major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis, 1987, 65, 257-264.	0.8	67
35	Eradicating the Burden of Atherosclerotic Cardiovascular Disease by Lowering Apolipoprotein B Lipoproteins Earlier in Life. Journal of the American Heart Association, 2018, 7, e009778.	3.7	67
36	Trajectories of Nonâ€"HDL Cholesterol Across Midlife. Journal of the American College of Cardiology, 2019, 74, 70-79.	2.8	67

#	Article	IF	Citations
37	Individualized Statin Benefit for Determining Statin Eligibility in the Primary Prevention of Cardiovascular Disease. Circulation, 2016, 133, 1574-1581.	1.6	66
38	Effect of moderate hypertriglyceridemia on the relation of plasma total and LDL apo B levels. Atherosclerosis, 1991, 89, 109-116.	0.8	65
39	Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome. Current Opinion in Lipidology, 2007, 18, 633-637.	2.7	64
40	Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B. Journal of Clinical Lipidology, 2007, 1, 256-263.	1.5	64
41	Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding. Journal of Lipid Research, 2018, 59, 1266-1275.	4.2	62
42	Does Low-Density Lipoprotein Size Add to Atherogenic Particle Number in Predicting the Risk of Fatal Myocardial Infarction?. American Journal of Cardiology, 2006, 97, 943-946.	1.6	61
43	Discordance analysis and the Gordian Knot of LDL and non-HDL cholesterol versus apoB. Current Opinion in Lipidology, 2014, 25, 461-467.	2.7	61
44	Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. Pharmacological Research, 2016, 103, 236-252.	7.1	60
45	Using Age- and Sex-Specific Risk Thresholds to Guide Statin Therapy. Journal of the American College of Cardiology, 2015, 65, 1633-1639.	2.8	58
46	The Role of Physicians in the Era of Predictive Analytics. JAMA - Journal of the American Medical Association, 2015, 314, 25.	7.4	55
47	Assessment of Reaching Goal in Patients with Combined Hyperlipidemia: Low-Density Lipoprotein Cholesterol, Nonâ€“High-Density Lipoprotein Cholesterol, or Apolipoprotein B. American Journal of Cardiology, 2005, 96, 36-43.	1.6	54
48	Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm. Current Opinion in Lipidology, 2004, 15, 433-438.	2.7	53
49	Risk of Premature Cardiovascular Disease vs the Number of Premature Cardiovascular Events. JAMA Cardiology, 2016, 1, 492.	6.1	52
50	How, when, and why to use apolipoprotein B in clinical practice. American Journal of Cardiology, 2002, 90, 48-54.	1.6	51
51	Regulation of plasma LDL: the apoB paradigm. Clinical Science, 2010, 118, 333-339.	4.3	49
52	Can Measurement of Serum Apolipoprotein B Replace the Lipid Profile Monitoring of Patients with Lipoprotein Disorders?. Clinical Chemistry, 2002, 48, 484-488.	3.2	48
53	Diabetes, Abdominal Adiposity, and Atherogenic Dyslipoproteinemia in Women Compared With Men. Diabetes, 2008, 57, 3289-3296.	0.6	45
54	Apolipoprotein A1 and B. Clinics in Laboratory Medicine, 2006, 26, 733-750.	1.4	44

#	Article	IF	Citations
55	The Expected 30-Year Benefits of Early Versus Delayed Primary Prevention of Cardiovascular Disease by Lipid Lowering. Circulation, 2020, 142, 827-837.	1.6	44
56	Is lower and lower better and better? A re-evaluation of the evidence from the Cholesterol Treatment Trialistsâ€™ Collaboration meta-analysis for low-density lipoprotein lowering. Journal of Clinical Lipidology, 2012, 6, 303-309.	1.5	42
57	Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. Current Cardiology Reports, 2020, 22, 67.	2.9	42
58	The Adipsin-ASP Pathway and Regulation of Adipocyte Function. Annals of Medicine, 1994, 26, 389-393.	3.8	41
59	Patient-Level Discordance in Population Percentiles of the Total Cholesterol to High-Density Lipoprotein Cholesterol Ratio in Comparison With Low-Density Lipoprotein Cholesterol and Nonâ€“High-Density Lipoprotein Cholesterol. Circulation, 2015, 132, 667-676.	1.6	41
60	Age and Cardiovascular Risk Attributable to Apolipoprotein B, Lowâ€Density Lipoprotein Cholesterol or Nonâ€Highâ€Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2016, 5, .	3.7	41
61	Effects of apolipoprotein B on lifespan and risks of major diseases including type 2 diabetes: a mendelian randomisation analysis using outcomes in first-degree relatives. The Lancet Healthy Longevity, 2021, 2, e317-e326.	4.6	41
62	Regulation by retinoic acid of acylation-stimulating protein and complement C3 in human adipocytes. Biochemical Journal, 2001, 356, 445-452.	3.7	40
63	Cardiovascular Death in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 335-340.	4.5	40
64	The spectrum of type III hyperlipoproteinemia. Journal of Clinical Lipidology, 2018, 12, 1383-1389.	1.5	40
65	Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. Atherosclerosis, 2000, 148, 215-229.	0.8	38
66	Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosisâ€”Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 2421-2423.	2.4	38
67	Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. European Journal of Preventive Cardiology, 2015, 22, 468-477.	1.8	37
68	ApoB versus non-HDL-C: What to do when they disagree. Current Atherosclerosis Reports, 2009, 11, 358-363.	4.8	36
69	Apolipoprotein B vs Low-Density Lipoprotein Cholesterol and Nonâ€“High-Density Lipoprotein Cholesterol as the Primary Measure of Apolipoprotein B Lipoprotein-Related Risk. JAMA Cardiology, 2022, 7, 257.	6.1	36
70	Reduced Body Weight, Adipose Tissue, and Leptin Levels Despite Increased Energy Intake in Female Mice Lacking Acylation-Stimulating Protein. Endocrinology, 2000, 141, 1041-1049.	2.8	34
71	Evaluation of the Pleiotropic Effects of Statins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 262-265.	2.4	32
72	A Targeted, Differential Top-Down Proteomic Methodology for Comparison of ApoA-I Proteoforms in Individuals with High and Low HDL Efflux Capacity. Journal of Proteome Research, 2018, 17, 2156-2164.	3.7	30

#	Article	IF	Citations
73	Cost-effectiveness of Low-density Lipoprotein Cholesterol Levelâ€“Guided Statin Treatment in Patients With Borderline Cardiovascular Risk. JAMA Cardiology, 2019, 4, 969.	6.1	30
74	World Heart Federation Cholesterol Roadmap. Global Heart, 2017, 12, 179.	2.3	30
75	An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB. Journal of Clinical Lipidology, 2016, 10, 1248-1258.	1.5	29
76	Non-HDL C equals apolipoprotein B: except when it does not!. Current Opinion in Lipidology, 2010, 21, 518-524.	2.7	28
77	Hepatic Cholesterol Homeostasis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 2481-2490.	2.4	28
78	Relation of Age, the Apolipoprotein B/Apolipoprotein A-I Ratio, and the Risk of Fatal Myocardial Infarction and Implications for the Primary Prevention of Cardiovascular Disease. American Journal of Cardiology, 2007, 100, 217-221.	1.6	27
79	When is equal not equal?. Journal of Clinical Lipidology, 2010, 4, 83-88.	1.5	27
80	A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention. JAMA Cardiology, 2018, 3, 1090.	6.1	27
81	ApoB in clinical care: Pro and Con. Atherosclerosis, 2019, 282, 169-175.	0.8	27
82	The clinical utility of apoB versus LDL-C/non-HDL-C. Clinica Chimica Acta, 2020, 508, 103-108.	1.1	27
83	High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. American Journal of Cardiology, 2001, 87, 792-793.	1.6	25
84	ApoB. Circulation Research, 2019, 124, 1425-1427.	4.5	25
85	Update on apolipoprotein B. Current Opinion in Lipidology, 2021, 32, 226-230.	2.7	25
86	The acylation-stimulating protein pathway and regulation of postprandial metabolism. Proceedings of the Nutrition Society, 1997, 56, 703-712.	1.0	24
87	Non-HDL cholesterol and apoB in dyslipidaemia. Clinical Science, 2008, 114, 149-155.	4.3	23
88	Taking a longer term view of cardiovascular risk: the causal exposure paradigm. BMJ, The, 2014, 348, g3047-g3047.	6.0	23
89	Nutritional management of hyperapoB. Nutrition Research Reviews, 2016, 29, 202-233.	4.1	22
90	Risks of Incident Cardiovascular Disease Associated With Concomitant Elevations in Lipoprotein(a) and Lowâ€Ðensity Lipoprotein Cholesterolâ€”The Framingham Heart Study. Journal of the American Heart Association, 2020, 9, e014711.	3.7	22

#	Article	IF	Citations
91	Targets for LDL-lowering therapy. Current Opinion in Lipidology, 2009, 20, 282-287.	2.7	21
92	ApoB versus non-HDL-cholesterol: Diagnosis and cardiovascular risk management. Critical Reviews in Clinical Laboratory Sciences, 2013, 50, 163-171.	6.1	21
93	Recent advances in the understanding and care of familial hypercholesterolaemia: significance of the biology and therapeutic regulation of proprotein convertase subtilisin/kexin typeÂ9. Clinical Science, 2015, 129, 63-79.	4.3	21
94	Modern prevalence of dysbetalipoproteinemia (Fredrickson-Levy-Lees type III hyperlipoproteinemia). Archives of Medical Science, 2020, 16, 993-1003.	0.9	20
95	The strengths and limitations of the ApoB/ApoA-I ratio to predict the risk of vascular disease: a hegelian analysis. Current Atherosclerosis Reports, 2007, 9, 261-265.	4.8	19
96	Influence of low-glucose peritoneal dialysis onÂserumÂlipids and apolipoproteins in the IMPENDIA/EDENÂtrials. Journal of Clinical Lipidology, 2014, 8, 441-447.	1.5	19
97	Differential impact of plasma triglycerides on HDL-cholesterol and HDL-apo A-I in a large cohort. Clinical Biochemistry, 2007, 40, 25-29.	1.9	18
98	Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein. Journal of Clinical Lipidology, 2012, 6, 427-433.	1.5	18
99	Temporal changes in concentrations of lipids and apolipoprotein B among adults with diagnosed and undiagnosed diabetes, prediabetes, and normoglycemia: findings from the National Health and Nutrition Examination Survey 1988–1991 to 2005–2008. Cardiovascular Diabetology, 2013, 12, 26.	6.8	18
100	The Effect of Individual Amino Acids on ApoB100 and Lp(a) Secretion by HepG2 Cells. Journal of Biological Chemistry, 1996, 271, 29136-29145.	3.4	17
101	The causal exposure model of vascular disease. Clinical Science, 2012, 122, 369-373.	4.3	16
102	Low-density lipoprotein-lowering strategies. Current Opinion in Cardiology, 2012, 27, 405-411.	1.8	16
103	The Benefit Model for Prevention of Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1175.	6.1	16
104	Type III Hyperlipoproteinemia: The Forgotten, Disregarded, Neglected, Overlooked, Ignored but Highly Atherogenic, and Highly Treatable Dyslipoproteinemia. Clinical Chemistry, 2019, 65, 225-227.	3.2	16
105	Sick Individuals and Sick Populations by Geoffrey Rose: Cardiovascular Prevention Updated. Journal of the American Heart Association, 2018, 7, e010049.	3.7	15
106	Key Questions About FamilialÂHypercholesterolemia. Journal of the American College of Cardiology, 2022, 79, 1023-1031.	2.8	15
107	Effects on apoB-100 secretion and bile acid synthesis by redirecting cholesterol efflux from HepG2 cells. Journal of Lipid Research, 2003, 44, 527-532.	4.2	14
108	Is the superiority of apoB over nonâ€“HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?. Journal of Clinical Lipidology, 2013, 7, 626-631.	1.5	14

#	Article	IF	Citations
109	Update on the detection and treatment of atherogenic low-density lipoproteins. Current Opinion in Endocrinology, Diabetes and Obesity, 2013, 20, 140-147.	2.3	14
110	ApoB vs non-HDL-C vs LDL-C as Markers of Cardiovascular Disease. Clinical Chemistry, 2021, 67, 1440-1442.	3.2	14
111	Pluralism of viewpoints as the antidote to intellectual conflict of interest in guidelines. Journal of Clinical Epidemiology, 2012, 65, 705-707.	5.0	13
112	Limitations in the conventional assessment of the incremental value of predictors of cardiovascular risk. Current Opinion in Lipidology, 2015, 26, 210-214.	2.7	12
113	The Enigma of Glucose and Lipid Metabolism. JAMA Cardiology, 2016, 1, 145.	6.1	12
114	Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA cholesterol guidelines get apoB right?. Journal of Clinical Lipidology, 2019, 13, 360-366.	1.5	12
115	Spectrum of Apolipoprotein AI and Apolipoprotein AII Proteoforms and Their Associations With Indices of Cardiometabolic Health: The CARDIA Study. Journal of the American Heart Association, 2021, 10, e019890.	3.7	12
116	Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias. European Journal of Clinical Investigation, 2011, 41, 423-433.	3.4	11
117	The Risk-Benefit Paradigm vs the Causal Exposure Paradigm: LDL as a primary cause of vascular disease. Journal of Clinical Lipidology, 2014, 8, 594-605.	1.5	11
118	Apolipoprotein B: the Rosetta Stone of lipidology. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, 28, 90-96.	2.3	10
119	Insights from apoB: from better diagnosis & therapy to the Medusa Hypothesis. Atherosclerosis Supplements, 2004, 5, 19-24.	1.2	9
120	The Editorâ€™s Roundtable: Expanded Versus Standard Lipid Panels in Assessing and Managing Cardiovascular Risk. American Journal of Cardiology, 2008, 101, 828-842.	1.6	9
121	Screening Strategies and Primary Prevention Interventions in Relatives of People With Coronary Artery Disease: A Systematic Review and Meta-analysis. Canadian Journal of Cardiology, 2015, 31, 649-657.	1.7	9
122	Serial versus single troponin measurements for the prediction of cardiovascular events and mortality in stable chronic haemodialysis patients. Nephrology, 2018, 23, 69-74.	1.6	9
123	Divergent responses of the liver to increased delivery of glucose or fatty acids: implications for the pathogenesis of type IV hyperlipoproteinemia. Atherosclerosis, 1998, 137, 291-301.	0.8	8
124	Shunts, channels and lipoprotein endosomal traffic: a new model of cholesterol homeostasis in the hepatocyte. Journal of Biomedical Research, 2017, 31, 95-107.	1.6	8
125	Comparison of Coronary Calcium Screening Versus Broad Statin Therapy for Patients at Intermediate Cardiovascular Risk. American Journal of Cardiology, 2012, 110, 530-533.	1.6	7
126	Race and Socioeconomic Differences Associated With Changes in Statin Eligibility Under the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	7

#	Article	IF	Citations
127	Do statins lower testosterone and does it matter?. BMC Medicine, 2013, 11, 58.	5.5	6
128	Improving Recognition of Cardiovascular Risk in Children. Journal of Pediatrics, 2014, 164, 228-230.	1.8	6
129	JCL roundtable: Apolipoproteins as causative elements in vascular disease. Journal of Clinical Lipidology, 2015, 9, 733-740.	1.5	6
130	Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm. Journal of Clinical Lipidology, 2021, 15, 104-115.e9.	1.5	6
131	The Role of the Liver in the Pathogenesis of Hyperlipidemia in Patients with End-St Age Renal Disease Treated with Continuous Ambulatory Peritoneal Dialysis. Peritoneal Dialysis International, 1996, 16, 207-211.	2.3	5
132	Lipid phenotypes at the extremes of high-density lipoprotein cholesterol: The very large database of lipids-9. Journal of Clinical Lipidology, 2015, 9, 511-518.e5.	1.5	5
133	Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte. Clinical Science, 2017, 131, 791-797.	4.3	5
134	Genetic Studies Help Clarify the Complexities of Lipid Biology and Treatment. JAMA - Journal of the American Medical Association, 2017, 318, 915.	7.4	5
135	An adverse lipoprotein phenotypeâ€"hypertriglyceridaemic hyperapolipoprotein Bâ€"and the long-term risk of type 2 diabetes: a prospective, longitudinal, observational cohort study. The Lancet Healthy Longevity, 2022, 3, e339-e346.	4.6	5
136	Apolipoprotein B, Diabetes and Medical Consensus. Annals of Clinical Biochemistry, 2010, 47, 2-3.	1.6	4
137	Calculation of LDL apoB. Atherosclerosis, 2014, 234, 373-376.	0.8	4
138	A Comparison of Lipids and apoB in Asian Indians and Americans. Global Heart, 2021, 16, 7.	2.3	4
139	The significance of early changes of positive and negative dp/dt following contrast ventriculography. Catheterization and Cardiovascular Diagnosis, 1976, 2, 337-345.	0.3	3
140	Should preclinical vascular abnormalities be measured in asymptomatic adults to improve cardiovascular risk stratification?. Current Opinion in Lipidology, 2011, 22, 454-459.	2.7	3
141	A failure of standardization or a failure of the process of standardization. Journal of Clinical Lipidology, 2018, 12, 1325-1326.	1.5	3
142	Prevention of cardiovascular disease: time for a course correction. European Heart Journal, 2020, 41, 3016-3017.	2.2	3
143	The case against ApoB and the ApoB:ApoA-I ratio: are they right?. Future Lipidology, 2008, 3, 257-264.	0.5	2
144	Response to Letter Regarding Article, â€œHyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Diseaseâ€. Circulation, 2015, 132, e203.	1.6	2

#	Article	IF	Citations
145	Is the Guideline Process Replicable and, if Not, What Does This Mean?. Progress in Cardiovascular Diseases, 2015, 58, 3-9.	3.1	2
146	Risk Prediction for Individualsâ€"Reply. JAMA - Journal of the American Medical Association, 2015, 314, 1875.	7.4	2
147	Impact of Heart Outcomes Prevention Evaluation Trial on Statin Eligibility for the Primary Prevention of Cardiovascular Disease. Circulation, 2017, 136, 1860-1862.	1.6	2
148	Effect of Selective Androgen Receptor Modulator on Cholesterol Efflux Capacity, Size, and Subspecies of HDL Particles. Journal of the Endocrine Society, 2022, 6, .	0.2	2
149	Differences between the effects of practolol and propranolol on the diastolic properties of the left ventricle. Clinical Pharmacology and Therapeutics, 1977, 21, 267-271.	4.7	1
150	Response by Labos et al to Letter Regarding Article, â€œEvaluation of the Pleiotropic Effects of Statins: A Reanalysis of the Randomized Trial Evidence Using Egger Regressionâ€• Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, e87-e88.	2.4	1
151	Clinical reasoning and prevention of cardiovascular disease. Journal of Clinical Lipidology, 2021, 15, 394-398.	1.5	1
152	Atherosclerosis Risk Factors. James J. Maciejko. Washington, DC: AACC Press, 2004, 192 pp., $49.00 ($39.00 AACC members), softcover. ISBN 1-59425-004-9.. Clinical Chemistry, 2005, 51, 1568-1568.	3.2	0
153	Approach and management of triglyceride based disorders. Journal of Indian College of Cardiology, 2015, 5, S66-S68.	0.1	0
154	Letter by Sniderman et al Regarding Article, â€œComparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Diseaseâ€• Circulation, 2019, 140, e822-e823.	1.6	0
155	How ApoB Measurements Could Improve Prevention of Cardiovascular Disease. Contemporary Cardiology, 2021, , 545-563.	0.1	0